Bioavailability Enhancement of Astilbin in Rats ... - ACS Publications

Subscriber access provided by UNIV OF LOUISIANA

Bioactive Constituents, Metabolites, and Functions

Bioavailability enhancement of astilbin in rat through zein-caseinate nanoparticles Dan Zheng, and Qing-Feng Zhang J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jafc.9b00018 • Publication Date (Web): 02 May 2019 Downloaded from http://pubs.acs.org on May 2, 2019

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 34

Journal of Agricultural and Food Chemistry

1

Bioavailability enhancement of astilbin in rat through zein-caseinate

2

nanoparticles

3

Dan Zheng, Qing-Feng Zhang*

4 5 6 7

Jiangxi Key Laboratory of Natural Product and Functional Food, College

8

of Food Science and Engineering, Jiangxi Agricultural University, Nanchang

9

330045, China

10 11 12

*Corresponding author, Tel & Fax: 86-791-3813863, E-mail: [email protected]

13

(Q.F. Zhang).

14

1

ACS Paragon Plus Environment


15

ABSTRACT

16

The astilbin encapsulated zein-caseinate nanoparticles were fabricated through

17

antisolvent method. The encapsulation and loading efficiency of astilbin in the

18

nanoparticles were determined by HPLC. The nanoparticles were characterized by

19

particle size, zeta potential, redispersibility, SEM, XRD, FTIR and DSC. Under the

20

optimal formulation of astilbin, zein and sodium caseinate with mass ratio of 1:1:2,

21

the size and zeta potential of the nanoparticles were 152.9 nm and -40.43 mV, while

22

the encapsulation and loading efficiency of astilbin were 80.1% and 21.8%,

23

respectively. The nanoparticles had good redispersibility in water without particle size

24

change after freeze-drying. The nanoparticles showed spherical shape with smooth

25

surface. XRD and DSC analysis showed that astilbin existed in amorphous form in the

26

nanoparticles. The interactions between astilbin and the protein were found, and

27

astilbin was encapsulated in nanoparticles rather than adsorbed. The diffusion of

28

astilbin from nanoparticles was significantly faster than that of astilbin suspensions in

29

both simulated gastric and intestinal fluids. Astilbin was relative stable in simulated

30

intestinal fluids, and the encapsulation in the nanoparticles showed slight stability

31

improvement effect. Pharmacokinetic study showed that the absolute bioavailability

32

of astilbin was improved from 0.32% to 4.40% in rat through nanoparticles

33

fabrication.

34

Keywords: Astilbin; Zein; Nanoparticles; Pharmacokinetics; Bioavailability

35

2


Page 2 of 34

Page 3 of 34


36

INTRODUCTION

37

Astilbin is the rhamnoside of dihydroquercetin. The flavonoid is presented in many

38

plant and plant-based foods with variety bioactivities.1-4 Particularly, the unique

39

selective immunosuppressive activity of astilbin has attracted increasing attention.5-9

40

Pharmacological studies revealed that astilbin could significantly inhibit delayed

41

hypersen-sitivity,5,6 collagen-induced arthritis,7,8 and immune liver injury.9 It has

42

reported that astilbin could selectively inhibit excess cellular immunity without

43

affecting humoral immunity. Its strong immunomodulatory activity shows no obvious

44

side-effects. Other compounds with similar activity has unfound yet. Astilbin may be

45

an attractive candidate for novel immunomodulator development.10 However, astilbin

46

is a poorly soluble compound with solubility of 0.221 g/L in water at 298 K.11 It is

47

also unstable in alkaline solution, and the isomerization and decomposition were

48

found.12 Due to the low solubility and permeability, the oral bioavailability of astilbin

49

is very poor. Wang found that the apparent permeability coefficient of astilbin was

50

less than 1*10-6 cm/s in Caco-2 cell and its oral bioavailability was only 0.066% in

51

rat.13 The study of Lei et al. showed that the oral bioavailability of astilbin was 2.01%

52

in rat.14 Hence, improving the bioavailability of astilbin is critical for its practical

53

application. By developing self micro-emulsifying drug delivery system, the

54

bioavailability of astilbin was enhanced 5.56-fold in beagle dogs.15 He et al. prepared

55

the solid dispersions of astilbin in PVP K30-Tween 80 combined carries.

56

Pharmacokinetic study in beagle dogs showed that the oral bioavailability of astilbin

57

solid dispersions was about 205% of that of astilbin. 16 3



Page 4 of 34

58

Zein is the main storage protein of corn with more than 50% of hydrophobic amino

59

acids. Hence, the protein is insoluble in water but has good solubility in 50-95%

60

ethanol-aqueous solution.17 With the decrease of ethanol concentration, zein will lost

61

its solubility and is able to self-assemble into micro- or nanoparticles,17 fiber

62

film.19 The specific structure is depended on the preparation method and conditions,

63

such as pH, zein concentration, shearing rate, etc.17 The unique self-assembly ability

64

of zein to form nanoparticle makes it a promising delivering carrier for nutraceuticals

65

and drugs.20 The internal hydrophobic environment of zein nanoparticles is suitable

66

for encapsulating of hydrophobic compounds. Furthermore, zein is an edible protein

67

with natural biocompatibility and biodegradability, and is generally recognized as safe

68

(GRAS) biomaterial.17 The encapsulation in zein nanoparticles could significantly

69

improve the stability, dispersibility and bioavailability of guest compounds.17,21

70

Penalva et al. fabricated the resveratrol and quercetin loaded zein nanoparticles

71

through desolvation method. The size of nanoparticles was 307 nm with resveratrol

72

loading of 80 μg/mg. The oral bioavailability of resveratrol was enhanced by

73

19.2-fold in rat.22 Similar results were found in quercetin loaded zein nanoparticles.23

74

Zou et al. designed TPGS 1000 emulsified zein nanoparticles to improve the oral

75

bioavailability of daidzin. Pharmacokinetic study showed the Cmax of daidzein in mice

76

plasma as well as the bioavailability were significantly increased.24 Sodium caseinate

77

is the sodium salt of casein, which is the main protein of milk. Sodium caseinate has

78

superb water solubility, and is widely used for emulsifying and thickening functions

79

in food industry. It has reported that sodium caseinate can adsorb on the surface of 4


18

and

Page 5 of 34


80

zein nanoparticles due to its amphiphilic and charged nature, which can prevent the

81

aggregation of colloids.25 Thus, sodium caseinate can be used as a stabilizer for zein

82

nanoparticles.

83

In the present study, zein-caseinate nanoparticles were fabricated to improve the

84

bioavailability of astilbin. The formulation was optimized through comparing the

85

encapsulation and loading efficiency of astilbin. The nanoparticles were characterized

86

by particle size, zeta potential, redispersibility, scanning electron microscopy (SEM),

87

differential scanning calorimeter (DSC), X-ray diffractometer (XRD), and Fourier

88

transform infrared spectroscopy (FTIR). The diffusion profile of astilbin from the

89

nanoparticles in simulated gastric (SGF) and intestinal fluids (SIF) was also studied.

90

Finally, pharmacokinetic study was carried out to confirm the bioavailability

91

enhancement of astilbin in rat.

92

MATERIALS AND METHODS

93

Chemicals. Astilbin (>98%) were purified from Rhizoma Smilacis Glabrae in our

94

laboratory, and was identified by UV, IR, MS, and NMR. HPLC grade acetonitrile

95

and methanol were purchased from Anhui Tedia High Purity Solvents Co., Ltd

96

(Anqin city, Anhui province,China). Zein was obtained from Sigma Co. Ltd (St.

97

Louis, MO, USA). Sodium caseinate, pepsin and pancreatin were purchased from

98

Beijing Solarbio Science & Technology Co., Ltd (Beijing, China). Milli-Q water was

99

used throughout the study. All other reagents used were analytical grade.

100

Preparation of astilbin encapsulated zein-caseinate nanoparticles. The

101

nanoparticles were prepared by antisolvent method described elsewhere.17 The mass 5



102

ratio of zein to astilbin in the nanoparticles was varied from 1:1 to 6:1, while the mass

103

ratio of zein to sodium caseinate was maintained at 1:2. Briefly, 100 mg of zein mixed

104

with 100, 50, 25 or 16.7 mg of astilbin were dissolved in 10 ml of 70% ethanol

105

solution, respectively. The mixture was dropped into 30 ml water contains 200 mg of

106

sodium caseinate using an injection syringe under quick magnetic stirring. The

107

dropping rate was about 2 mL/min. After stirring for another 60 min, the

108

nanoparticles suspensions were concentrated to 25 ml by rotary evaporators at 50

109

oC.The

110

large particles and free astilbin. Then, a little part of the suspensions were used for

111

encapsulated astilbin determination, particle size and zeta-potential analysis, and the

112

rest were freeze-dried.

suspensions were subsequently centrifugated at 2000 g for 10 min to remove

113

Particle size, Polydispersity index (PDI) and Zeta-potential analyses. The

114

particle size and zeta-potential of nanoparticles were measured by dynamic light

115

scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments Ltd., UK). The

116

measurement was replicated three times for each sample.

117

Encapsulation and loading efficiency. The encapsulated astilbin in nanoparticles

118

was determined by HPLC method. The encapsulation efficiency (EE) and loading

119

efficiency (LE) were calculated with the equations:

120

EE=

121

LE=

122

Briefly, the nanoparticles were dissolved in 70% ethanol. After appropriate dilution, a

123

10 μL aliquot of sample was injected in an Agilent 1260 HPLC system (Agilent

𝐴𝑠𝑡𝑖𝑙𝑏𝑖𝑛 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠(𝑚𝑔) 𝑡𝑜𝑡𝑎𝑙 𝑎𝑠𝑡𝑖𝑙𝑏𝑖𝑛 𝑢𝑠𝑒𝑑 (𝑚𝑔)

×100%

𝐴𝑠𝑡𝑖𝑙𝑏𝑖𝑛 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠(𝑚𝑔) 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑦 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠(𝑚𝑔)

×100%

6


Page 6 of 34

Page 7 of 34


124

Technologies, Palo Alto, CA, USA). The HPLC conditions were the same as we

125

described before.12

126

Scanning electron microscopy (SEM) analysis. The freeze-dried nanoparticles

127

(Ast-Zein1:1) and its redispersion solution were used for morphology characterization

128

by SEM (FEI Quanta 250 FEG, FEI Inc., OR, USA). The redispersion solution was

129

first dropped on a conductive glass and then dried naturally. Before imaging, the

130

samples were coated with a thin layer of gold first.

131

Differential scanning calorimeter (DSC) analysis. DSC analysis was carried on a

132

NETZSCH DSC 214 polyma instrument (Netzsch, Germany). About 5 mg of

133

freeze-dried nanoparticles (Ast-Zein1:1) was added to a standard aluminum pan and

134

hermetically sealed. The pan was placed in glass desicator for 24 h to exclude the

135

influence of moisture. An empty sealed aluminum pan was used as control. Samples

136

were heated from 50 to 300 oC at rate of 12 oC/min with a constant purging of dry

137

nitrogen at rate of 50 mL/min. The thermal characteristics of astilbin, physical

138

mixture of zein and sodium caseinate (with mass ratio of 1:2) were also analyzed.

139

X-ray diffractometer (XRD) analysis. XRD patterns of Ast-Zein1:1 nanoparticles

140

and astilbin were performed on a Bruker D8 ADVANCE diffractometer (Bruker,

141

Germany). The instrument was equipped with a copper anode. The working

142

accelerating voltage and tube current were 40 kV, 40 mA, respectively. The pattern

143

was recorded over an angular range from 5o to 60o in continuous mode with a step

144

size of 0.02o and scanning speed of 2o/min.

145

Fourier transform infrared spectroscopy (FTIR) analysis. FTIR spectroscopy of 7



146

Ast-Zein1:1 nanoparticles, astilbin and physical mixture of zein and sodium caseinate

147

(with mass ratio of 1:2) were recorded on a Nicolet 5700 FTIR spectrometer (Nicolet,

148

USA) by the KBr method.

149

In vitro diffusion of astilbin from the nanoparticle in simulated gastric (SGF)

150

and intestinal fluids (SIF). SGF (pH 1.2) and SIF (pH 6.8) were prepared in

151

accordance with USP XXII.19. Ast-Zein1:1 nanoparticles and astilbin were dispersed

152

in 5 ml of SGF or SIF (with enzyme) with astilbin concentration of 3 mg/mL. The

153

solution was put into a dialysis bag (molecular cutoff: 7 kDa) and then placed in

154

beaker containing 500 ml of SGF or SIF (without enzyme) under magnetic stirring at

155

37 oC. At different time intervals, astilbin concentration in the beaker was analyzed by

156

HPLC.

157

Stability of free astilbin and Ast-Zein1:1 nanoparticles in simulated intestinal

158

fluids (SIF). Astilbin solution was prepared in 60% ethanol with concentration of 1

159

mg/mL. Ast-Zein1:1 nanoparticles were dispersed in water with astilbin concentration

160

of 1 mg/mL. A 1.0 mL aliquot of the two solutions were mixed with 9 mL of SIF

161

(without enzyme), respectively. The mixture was incubated at 37 oC in waterbath. At

162

different time intervals, the remaining astilbin was determined by HPLC.

163

Pharmacokinetic studies in rats. The animal studies were complied with the

164

guidelines of Jiangxi Agricultural University on animal care. Sprague-Dawley (SD)

165

rats were obtained from Hunan slack Jing Da laboratory animal Co., Ltd (Changsha

166

City, Hunan province, China). The rats were breed in a controlled environment

167

conditions with 12/12 h light/dark cycle and temperature of 23-25 ℃ . Before 8


Page 8 of 34

Page 9 of 34


168

pharmacokinetic study, rats were fasted overnight with access to water. Eighteen rats

169

were randomly divided into three groups (n=6) with mean weight of 300±15 g. For

170

nanoparticles colloidal solution, freeze-dried Ast-Zein1:1 nanoparticles were dispersed

171

in warm water (~40 oC) with astilbin concentration of 6 mg/mL. Similarly, astilbin

172

suspensions were prepared by suspending astilbin powder (pass through 100 mesh,

173

with average size of about 150 μm) in warm water (~40 oC) directly with

174

concentration of 6 mg/mL. Because the solubility of astilbin is only about 0.2 mg/mL,

175

it will precipitate soon. Thus, before oral administration, the suspensions should be

176

shocked intensely. Group I and II were orally administered 1 mL of nanoparticles

177

colloidal solution and astilbin suspensions with dose of 20 mg astilbin/kg body weight,

178

respectively. Group III received intravenous (iv) administration of 0.3 ml astilbin

179

solution (2 mg/mL in 10% ethanol) through caudal vein with dose of 2 mg astilbin/kg

180

body weight. The iv solution was prepared by 5 times dilution of astilbin dissolved in

181

50% ethanol (10 mg/mL) with water. Blood samples (~200 μL) were obtained from

182

tail veins into K2-EDTA pretreated tubes at 0.167, 0.5, 1, 2, 3, 4, 6 and 8 h after

183

administration. After centrifugation at 2000 g for 10 min, the plasma samples were

184

obtained and stored at −80 °C before analysis.

185

A liquot of 50 μL plasma sample was mixed with 150 μL of methanol containing

186

350 ng/mL rutin (used as internal standard, IS). Then, a 5 μL liquot of acetic acid was

187

added. The mixture was vortexed for 2 min to precipitate endogenous proteins. After

188

centrifugation at 10000 g for 10 min, the supernatant was transferred to a new 1.5 mL

189

tube and concentrated to about 100 μL on 75 oC waterbath for 12 min. The solution 9



190

was centrifuged at 10000 g for 10 min again, and the supernatant was used for astilbin

191

determination.

192

The astilbin concentration was determined on an Agilent 1260 HPLC system

193

equipped with an autosampler and DAD detector. A symmetry C18 column (4.6 mm

194

× 250 mm, 5.0 μm; Waters, USA) was used. The mobile phase consisted of 24%

195

acetonitrile and 76% water (with 0.1% acetic acid). The flow rate was 1.0 mL/min

196

with column temperature of 40 oC and detection wavelength of 291nm (for astilbin)

197

and 355 nm (for rutin). The injection volume was 50 μL and the analysis duration was

198

10 min.

199

Calibration curve was obtained in triplicates by plotting the peak area ratio

200

(astilbin/rutin) against the astilbin concentration (16, 32, 64, 128, 256, 515, 721, 1030,

201

5150, 10300 ng/mL in plasma). The regression equation is Y=2.2604X with linear

202

coefficient of 0.9995, where Y is the peak area ratio and X is the concentration of

203

astilbin in plasma (μg/mL).

204

The pharmacokinetic data were simulated by Drug and Statistics (DAS) software

205

(version 2.0) using a non-compartmental statistical model to calculated the

206

pharmacokinetic parameters, including the maximal serum concentration (Cmax), the

207

time in which Cmax is reached (tmax), the area under the concentration-time curve

208

(AUC), the mean residence time (MRT), the clearance (CL), and the half-life in the

209

terminal phase (t1/2). Furthermore, the absolute bioavailability (Fr, %) of astilbin was

210

calculated by the equation

211

Fr(%) =

AUCoral AUCiv

× 100

10


Page 10 of 34

Page 11 of 34


212

Statistical analysis. Data were expressed as mean ± standard deviation of triplicates.

213

Data analysis and plotting were performed with software of Origin 7.0 (Origin Lab

214

Co., Northampton, MA, USA). One-way ANOVA was used for statistical analysis.

215

Differences were considered significant when P

Bioavailability Enhancement of Astilbin in Rats ... - ACS Publications

Recommend Documents